JP2016514160A5 - - Google Patents

Download PDF

Info

Publication number
JP2016514160A5
JP2016514160A5 JP2016502881A JP2016502881A JP2016514160A5 JP 2016514160 A5 JP2016514160 A5 JP 2016514160A5 JP 2016502881 A JP2016502881 A JP 2016502881A JP 2016502881 A JP2016502881 A JP 2016502881A JP 2016514160 A5 JP2016514160 A5 JP 2016514160A5
Authority
JP
Japan
Prior art keywords
substituted
unsubstituted
cancer
compound
heteroaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502881A
Other languages
English (en)
Japanese (ja)
Other versions
JP6422936B2 (ja
JP2016514160A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/028730 external-priority patent/WO2014153023A1/en
Publication of JP2016514160A publication Critical patent/JP2016514160A/ja
Publication of JP2016514160A5 publication Critical patent/JP2016514160A5/ja
Application granted granted Critical
Publication of JP6422936B2 publication Critical patent/JP6422936B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502881A 2013-03-14 2014-03-14 ５−ブロモ−インジルビン Expired - Fee Related JP6422936B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361783290P 2013-03-14 2013-03-14
US61/783,290 2013-03-14
PCT/US2014/028730 WO2014153023A1 (en) 2013-03-14 2014-03-14 5-bromo-indirubins

Publications (3)

Publication Number Publication Date
JP2016514160A JP2016514160A (ja) 2016-05-19
JP2016514160A5 true JP2016514160A5 (enExample) 2017-04-13
JP6422936B2 JP6422936B2 (ja) 2018-11-14

Family

ID=51581389

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016502881A Expired - Fee Related JP6422936B2 (ja) 2013-03-14 2014-03-14 ５−ブロモ−インジルビン

Country Status (12)

Country Link
US (4) US20160068517A1 (enExample)
EP (1) EP2970310B1 (enExample)
JP (1) JP6422936B2 (enExample)
KR (1) KR102275112B1 (enExample)
CN (1) CN105283456B (enExample)
AU (1) AU2014236370C1 (enExample)
BR (1) BR112015023383A2 (enExample)
CA (1) CA2902914A1 (enExample)
EA (1) EA035877B1 (enExample)
IL (1) IL240916A0 (enExample)
MX (1) MX2015013021A (enExample)
WO (1) WO2014153023A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2015013021A (es) 2013-03-14 2016-07-14 Nat And Kapodistrian University Of Athens 5-bromo-indirrubinas.
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins
CN114224907A (zh) 2015-07-02 2022-03-25 希望之城 包括硫代磷酸化寡脱氧核苷酸的化合物和组合物及其使用方法
AU2018358582B2 (en) * 2017-10-31 2021-06-10 Pelemed Co., Ltd. Pharmaceutical composition for prevention or treatment of acute myeloid leukemia or metastatic breast cancer
KR102443617B1 (ko) * 2019-12-06 2022-09-16 광주과학기술원 근감소증 또는 근위축증의 예방 또는 치료용 약제학적 조성물
KR102744517B1 (ko) * 2022-02-14 2024-12-19 주식회사 펠레메드 신규한 헤테로비시클릭 잔기를 갖는 인디루빈 유도체 및 이의 용도

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
EP0495421B1 (en) 1991-01-15 1996-08-21 Alcon Laboratories, Inc. Use of carrageenans in topical ophthalmic compositions
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
FR2801216A1 (fr) * 1999-11-23 2001-05-25 Centre Nat Rech Scient Utilisation de derives d'indirubine pour la fabrication de medicaments
US20050154046A1 (en) 2004-01-12 2005-07-14 Longgui Wang Methods of treating an inflammatory-related disease
EP1746887A1 (en) * 2004-05-12 2007-01-31 Bayer CropScience GmbH Plant growth regulation
US20060078494A1 (en) * 2004-09-24 2006-04-13 Sapphire Therapeutics, Inc. Use of inhibitors of 24-hydroxylase in the treatment of cancer
CA2633069A1 (en) * 2005-12-23 2007-09-07 Centre National De La Recherche Scientifique (Cnrs) New 3'-, 7-substituted indirubins and their applications
ATE529402T1 (de) * 2008-08-01 2011-11-15 Centre Nat Rech Scient 3',6-substituierte indirubine und ihre biologischen anwendungen
EP2518139A1 (en) * 2011-04-27 2012-10-31 Universitätsklinikum Jena Use of indirubin derivatives for producing pluripotent stem cells
EP2733140A4 (en) 2011-07-15 2014-11-26 Univ Nihon INDIRUBINE DERIVATIVE WITH HIGHLY SELF-ACTIVE CYTOTOXICITY FOR POOR TUMORS
US10435367B2 (en) * 2013-03-14 2019-10-08 City Of Hope Indirubin derivatives, and uses thereof
MX2015013021A (es) * 2013-03-14 2016-07-14 Nat And Kapodistrian University Of Athens 5-bromo-indirrubinas.
US20150259288A1 (en) 2014-03-14 2015-09-17 City Of Hope 5-bromo-indirubins

Similar Documents

Publication Publication Date Title
JP2016514160A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2019529500A5 (enExample)
JP2012508252A5 (enExample)
JP2019501223A5 (enExample)
JP2019517487A5 (enExample)
JP2013056930A5 (enExample)
JP2018507877A5 (enExample)
JP2014525464A5 (enExample)
JP2017537080A5 (enExample)
JP2009513703A5 (enExample)
JP2017504635A5 (enExample)
JP2017538678A5 (enExample)
JP2013533879A5 (enExample)
JP2017506250A5 (enExample)
JP2014139226A5 (enExample)
JP2017509586A5 (enExample)
RU2014115847A (ru) Пирролопиримидиновые соединения для лечения злокачественной опухоли
JP2015517574A5 (enExample)
RU2016134751A (ru) Соединения
JP2017502092A5 (enExample)
JP2014534269A5 (enExample)
JP2018515563A5 (enExample)
JP2016531126A5 (enExample)
JP2018516994A5 (enExample)